(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Hilary Duff releases 'Mature,' her 1st song in 10 years - 2Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\
- 3Israel's fractured opposition hands Netanyahu a full term
- 4Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- 5Meet the Stars of the Feline World: Well known Pet Feline Varieties
- Flu is rising rapidly, driven by a new variant. Here's what to know
- Land Rover Just Unveiled Its Dakar Rally Defender
- China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
- Pick Your Number one breakfast food
- Intriguing Social Unesco World Legacy Locales All over The Planet
- We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- This Huge Ocean Beast Shifts Sharks’ Evolutionary Timeline
- South America's Memorable Destinations: A Movement Guide
